Shulamit Rizel
About
In The Last Decade
Shulamit Rizel
24 papers receiving 392 citations
Peers
Comparison fields: 5 of 49
- Reproductive Medicine 175
- Oncology 129
- Genetics 127
- Cancer Research 113
- Surgery 96
Countries citing papers authored by Shulamit Rizel
This map shows the geographic impact of Shulamit Rizel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shulamit Rizel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shulamit Rizel more than expected).
Fields of papers citing papers by Shulamit Rizel
This network shows the impact of papers produced by Shulamit Rizel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shulamit Rizel. The network helps show where Shulamit Rizel may publish in the future.
Co-authorship network of co-authors of Shulamit Rizel
This figure shows the co-authorship network connecting the top 25 collaborators of Shulamit Rizel. A scholar is included among the top collaborators of Shulamit Rizel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shulamit Rizel. Shulamit Rizel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 4 | |
| 3 | 1 | |
| 4 | 54 | |
| 5 | 11 | |
| 6 | 21 | |
| 7 | 54 | |
| 8 | 48 | |
| 9 | 3 | |
| 10 | 62 | |
| 11 | Intraperitoneal chemotherapy with cisplatin and etoposide in ovarian carcinoma patients who are clinically in complete remission. | 3 |
| 12 | Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second look laparotomy. A reassessment based on mature data. | 4 |
| 13 | 5 | |
| 14 | 17 | |
| 15 | 11 | |
| 16 | Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study. | 1 |
| 17 | Acute renal failure associated with intraperitoneal cisplatin chemotherapy with systemic thiosulfate protection in ovarian cancer patients. | 6 |
| 18 | 7 | |
| 19 | 44 | |
| 20 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.